FDA WARNING_LETTER - premiumlightsupplier.com - April 12, 2022

The FDA and DEA issued a Warning Letter to www.premiumlightsupplier.com on March 30, 2022, for unlawfully selling Schedule II stimulants, including amphetamine drug products, to U.S. consumers over the internet.

The DEA's review found the website violates the Ryan Haight Online Pharmacy Consumer Protection Act (RHA) by offering to distribute or dispense controlled substances and advertising their sale without a modified DEA registration. The website is classified as an "online pharmacy" and acts as an agent bringing together buyers and sellers of controlled substances without proper authorization.

The FDA's review identified that the website introduces misbranded amphetamine drug products, specifically "Adderall 20mg | 30mg," into interstate commerce, violating sections 301(a), 301(k), and 503(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Adderall is a prescription-only drug with a high potential for abuse and dependence, requiring supervision by a licensed practitioner. Offering it without a prescription misbrands the drug and jeopardizes patient safety.

The letter emphasizes the public health risks associated with the diversion and nonmedical use of Schedule II stimulants, including rising overdose mortality and polysubstance use.

The website is required to take prompt corrective action and notify both DEA and FDA in writing within 15 working days of receipt, detailing steps taken to address violations and prevent